Incretin agents in type 2 diabetes

Canadian Family Physician

Volumn 56, Issue 7, 2010, Pages 639-648

  Ross, Stuart A ^a   Ekoé, Jean Marie ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIPHASIC INSULIN; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INCRETIN; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

ACUTE PANCREATITIS; ADD ON THERAPY; BODY WEIGHT; CARCINOMA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG TOLERABILITY; EMBASE; EVIDENCE BASED MEDICINE; GENE OVEREXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; LIFESTYLE MODIFICATION; MEDLINE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREATITIS; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; STOMACH EMPTYING; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADULT; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; EVIDENCE-BASED MEDICINE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INCRETINS; PEPTIDES; VENOMS;

EID: 77956581914     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. International Diabetes Federation. IDF diabetes atlas. 4th ed. Brussels, Belgium: International Diabetes Federation; 2009. Available from: www.diabetesatlas.org. Accessed 2010 May 31.
2. National Diabetes Education Program. Diabetes medications supplement. Working together to manage diabetes. Bethesda, MD: National Diabetes Education Program; 2007. Available from: http://ndep.nih.gov/media/ Drug-tables- supplement.pdf. Accessed 2010 May 31.
3. Canadian Diabetes Association. Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32(Suppl 1):S1-201.
4. Harris SB, Ekoé JM, Zdanowicz Y, Webster-Bogaert S. Glycemic control and morbidity in the Canadian primary care setting (results of the Diabetes in Canada Evaluation study). Diabetes Res Clin Pract 2005;70(1):90-7. (Pubitemid 41207652)
5. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368(9548):1696-705.
6. Chia CW, Egan JM. Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab 2008;93(10):3703-16. Epub 2008 Jul 15.
7. Gilbert MP, Pratley RE. Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus. Am J Med 2009;122(6 Suppl):S11-24.
8. Kendall DM, Cuddihy RM, Bergenstal RM. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Am J Med 2009;122(6 Suppl):S37-50.
9. Mudaliar S, Henry RR. Incretin therapies: effects beyond glycemic control. Am J Med 2009;122(6 Suppl):S25-36.
10. Nauck MA. Unraveling the science of incretin biology. Am J Med 2009;122(6 Suppl):S3-10.
11. Vilsbøll T, Holst JJ. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 2004;47(3):357-66. Epub 2004 Feb 13. (Pubitemid 38491230)
12. McIntosh CHS. Incretin-based therapies for type 2 diabetes. Can J Diabetes 2008;32(2):131-9.
13. Augeri DJ, Robl JA, Betebenner DA, Magnin DR, Khanna A, Robertson JG, et al. Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005;48(15):5025-37. (Pubitemid 41033142)
14. DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32(9):1649-55. Epub 2009 May 28.
15. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9(2):194-205. (Pubitemid 46206563)
16. Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008;10(1):82-90. Epub 2007 Nov 22. (Pubitemid 350302434)
17. Pinelli NR, Cha R, Brown MB, Jaber LA. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis. Ann Pharmacother 2008;42(11):1541-51. Epub 2008 Oct 28.
18. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373(9662):473-81. Epub 2008 Sep 24.
19. Garber AJ, Henry R, Ratner R. Monotherapy with liraglutide, a once-daily human GLP-1 analog, provides sustained reductions in A1c, FPG, and weight compared with glimepiride in type 2 diabetes: LEAD-3 Mono 2-year results. Diabetes 2009;58(Suppl 1):A42-3.
20. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143(8):559-69.
21. Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover non-inferiority trial. Clin Ther 2007;29(11):2333-48. (Pubitemid 350298125)
22. Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007;50(2):259-67. Epub 2006 Dec 8.
23. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009;52(10):2046-55. Epub 2009 Aug 15.
24. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27(11):2628-35. (Pubitemid 39441462)
25. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28(5):1092-100.
26. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28(5):1083-91. (Pubitemid 40616617)
27. Zinman B, Hoogwerf BJ, Duran Garcia S, Milton DR, Giaconia JM, Kim DD, et al. The effect of adding exenatide to a thiazolidinedione in sub-optimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007;146(7):477-85. Erratum in: Ann Intern Med 2007;146(12):896.
28. Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, et al. Interim analysis of the effects of exenatide treatment on A1c, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006;8(4):436-47.
29. Linnebjerg H, Park S, Kothare PA, Trautmann ME, Mace K, Fineman M, et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept 2008;151(1-3):123-9. Epub 2008 Jul 16.
30. Amylin Pharmaceuticals. Byetta (exenatide) injection [prescribing information]. San Diego, CA: Amylin Pharmaceuticals; 2009. Available from: http:// pi.lilly.com/us/byetta-pi.pdf. Accessed 2009 Aug 1.
31. Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, doubleblind, placebo-controlled, parallel-group study. Clin Ther 2008;30(8):1448-60. Erratum in: Clin Ther 2008;30(10):1937.
32. Marre M, Shaw J, Brandel M, Bebakar WM, Kamaruddin NA, Strand J, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26(3):268-78.
33. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 Study. Diabetes Care 2009;32(1):84-90. Epub 2008 Oct 17.
34. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009;32(7):1224-30. Epub 2009 Mar 16.
35. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008;(2):CD006739. (Pubitemid 351807276)
36. Midlands Therapeutics Review & Advisory Committee. Vildagliptin: summary of product characteristics. Staffordshire, UK: Midlands Therapeutics Review & Advisory Committee; 2008. Available from: www.keele.ac.uk/schools/ pharm/ MTRAC/ProductInfo/verdicts/V/Vildagliptin.pdf. Accessed 2009 Feb 1.
37. Merck Frosst Canada Ltd. Januvia [product monograph]. Ottawa, ON: Health Canada Drug Product Database; 2010. Available from: http://webprod.hc-sc. gc.ca/dpd-bdpp/dispatch-repartition.do?lang=eng. Accessed 2009 Feb 1.
38. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams- Herman DE, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29(12):2632-7. (Pubitemid 44912190)
39. Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, Kato N, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008;79(2):291-8. Epub 2007 Oct 22.
40. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30(8):1979-87. Epub 2007 May 7. Erratum in: Diabetes Care 2008;31(8):1713.
41. Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP, et al. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin 2007;23(6):1329-39. Epub 2007 Apr 30. (Pubitemid 46998442)
42. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49(11):2564-71. Epub 2006 Sep 26. (Pubitemid 44912190)
43. Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007;61(1):171-80. Epub 2006 Dec 5.
44. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29(12):2638-43. (Pubitemid 44912191)
45. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9(5):733-45. Epub 2007 Jun 26. (Pubitemid 47261855)
46. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28(10):1556-68. (Pubitemid 44841980)
47. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008;24(10):2943-52. Epub 2008 Sep 10.
48. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract 2007;76(1):132-8. Epub 2007 Jan 12.
49. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007;39(3):218-23.
50. Kikuchi M, Abe N, Kato M, Terao S, Mimori N, Tachibana H. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2009;83(2):233-40. Epub 2008 Dec 31.
51. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006;38(6):423-8.
52. Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005;7(6):692-8. (Pubitemid 41601073)
53. Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Jauffret S, et al. Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008;10(8):675-82. Epub 2007 Nov 22. (Pubitemid 352044298)
54. Ahrén B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004;27(12):2874-80. (Pubitemid 39565052)
55. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30(4):890-5. Epub 2007 Feb 2.
56. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007;50(6):1148-55. Epub 2007 Mar 27.
57. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007;9(2):166-74. (Pubitemid 46206560)
58. Rosenstock J, Kim SW, Baron MA, Camisasca RP, Cressier F, Couturier A, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007;9(2):175-85. (Pubitemid 46206561)
59. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24(1):275-86. (Pubitemid 351160260)
60. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374(9683):39-47. Epub 2009 Jun 8.
61. Ahrén B. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care 2007;30(6):1344-50. Epub 2007 Mar 2. (Pubitemid 46871136)
62. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998;47(11):1663-70.
63. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005;62(2):173-81. (Pubitemid 40674548)
64. Noel RA, Braun DK, Patterson R, Bloomgren G. Increased risk of acute pancreatitis observed in patients with type 2 diabetes. Pharmacoepidemiol Drug Saf 2008;17(Suppl 1):S254-5.
65. US Food and Drug Administration. Byetta (exenatide) - renal failure. Silver Spring, MD: US Food and Drug Administration; 2009. Available from: www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm188703.htm. Accessed 2009 May 14.
66. Jacobsen L, Hindsberger C, Robson R, Zdravkovic M. Pharmacokinetics of the long-acting human GLP-1 analogue liraglutide in subjects with renal impairment Diabetologia 2007;50(Suppl.1):S352.
67. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992;267(11):7402-5.
68. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003;26(8):2370-7.
69. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372(9645):1240-50. Epub 2008 Sep 7.
70. Rosenstock J, Reusch J, Bush M, Yang F, Stewart M; Albiglutide Study Group. The potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009;32(10):1880-6. Epub 2009 Jul 10.
71. Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000;43(9):1664-9.
72. Degn KB, Juhl CB, Sturis J, Brock B, Chandramouli V, Rungby J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004;53(5):1187-94. (Pubitemid 38569002)
73. Elbrønd B, Jakobsen G, Larsen S, Agersø H, Jensen LB, Rolan P, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a singledose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002;25(8):1398-404. (Pubitemid 41071152)
74. Colagiuri S, Frid A, Zdravkovic M, Le-Thi TD, Vaag A. The once-daily human GLP-1 analog liraglutide reduces systolic blood pressure in patients with type 2 diabetes. Diabetes 2008;57(Suppl 1):A164-5.
75. Matthews D, Marre M, Le-Thi TD, Zdravkovic M, Simó R. Liraglutide, a once-daily human GLP-1 analog, significantly improves beta-cell function in subjects with type 2 diabetes. Diabetes 2008;57(Suppl 1):A150-1.
76. Riche DM, East HE, Riche KD. Impact of sitagliptin on markers of ?-cell function: a meta-analysis. Am J Med Sci 2009;337(5):321-8.
77. Aaboe K, Vilsboll T, Knop FK, Deacon CF, Holst JJ, Madsbad S, et al. Twelve weeks treatment with the DPP-4 inhibitor sitagliptin improves the insulin-secreting capacity of the ?-cells in subjects with type 2 diabetes mellitus - a randomized trial. Diabetes 2009;58(Suppl 1):A163.
78. Davies M, Lavalle-Gonzalez F, Storms F, Gomis R. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial. Diabetes Obes Metab 2008;10(5):387-99. Epub 2008 Mar 18.
79. Jadzinsky M, Pfutzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009;11(6):611-22.
80. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358(24):2545-59. Epub 2008 Jun 8.
81. ADVANCE Collaborative Group; Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358(24):2560-72. Epub 2008 Jun 8.
82. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360(2):129-39. Epub 2008 Dec 17. Erratum in: N Engl J Med 2009;361(10):1024-5, 1028.
83. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29(8):1963-72. Erratum in: Diabetes Care 2006;49(11):2816-8.
84. Hanna A, Zinman B, Gerstein H, Knudsen LB, Baggio L, Yale JF. Glucagonlike peptide-1 based therapies. Endocrinol Sci Update 2008;218(025):1-6. Available from: www.endocrinologyupdate.ca/crus/218-025%20 English%20(6%20pages).pdf. Accessed 2010 May 31.